The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) ("KaloBios" or the "Company") securities during the period between November 19, 2015 and December 17, 2015, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until February 16, 2016 to seek appointment as lead plaintiff. If you have suffered a loss from investment in KaloBios securities purchased on or after November 19, 2015 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at email@example.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company securities during the Class Period. Brower Piven also encourages anyone with information regarding the Company's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that Martin Shkreli, the Chief Executive Officer of KaloBios, was engaged in a scheme involving the illegal use of stock from Retrophin to pay off debts associated with other unrelated business ventures the revelation of which would likely undermine the Company's operations and prospects.